Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Isofol Medical AB ( (SE:ISOFOL) ) just unveiled an update.
Isofol Medical reported a first-quarter loss of SEK 15.1 million on zero revenue, while boosting cash holdings to SEK 110.7 million, supported by strong uptake of its TO1 warrants that raised about SEK 18.9 million before costs. Management highlighted a reinforced financial position despite slower-than-expected patient recruitment and earnings per share of minus SEK 0.05.
Operationally, the company advanced its arfolitixorin program, presenting study design data at ASCO-GI and releasing preliminary phase Ib results showing tumor shrinkage in all evaluated patients without dose-limiting toxicities, with half deemed candidates for surgery. Regulatory momentum continued as Germany’s BfArM approved an optimized design for the phase Ib/II trial, broadening inclusion criteria, enabling direct comparison with leucovorin, and allowing an additional study center to accelerate recruitment, while Isofol also expanded its global license for arfolitixorin into autism spectrum disorder.
More about Isofol Medical AB
Isofol Medical AB is a clinical-stage biotechnology company focused on improving outcomes for patients with severe forms of cancer. Its lead drug candidate, arfolitixorin, is a next‑generation folate therapy designed to enhance the efficacy of standard treatments for solid tumors and is currently being evaluated in a phase Ib/II trial in colorectal cancer, the world’s third most common cancer.
Average Trading Volume: 1,746,313
Technical Sentiment Signal: Sell
Current Market Cap: SEK229.2M
Find detailed analytics on ISOFOL stock on TipRanks’ Stock Analysis page.